Leveraging Integrated Specialty Pharmacy Programs to Optimize Oncology Practice Management

Quality measures in oncology are critical for improving patient outcomes, reducing adverse events, and meeting regulatory standards under value-based care models. In health systems that have an integrated specialty pharmacy program, pharmacists play a critical role on the care team. The integrated specialty pharmacy program is a coordinated, patient-focused model that combines clinical pharmacy expertise, streamlined workflows, and multidisciplinary collaboration to optimize safe, effective, and personalized care for patients with complex conditions. The clinical pharmacist contributions span medication safety, adherence, toxicity management, and cost avoidance, which are areas that directly impact patient outcomes and organizational performance. As medication experts, pharmacists are uniquely positioned to influence quality measures through targeted interventions.

What Defines Oncology Quality Measures?

Oncology quality measures are standardized tools used to assess how well cancer care is delivered.  Measuring outcomes and processes consistently helps healthcare teams reduce variation in care, improves performance, and ensures they are meeting established clinical guidelines, improving patient experience, and treatment results. Measures include:

• Medication Adherence
• Medication Reconciliation & Patient Safety: Prescribing Errors and Adverse Drug Events
• Cost Efficiency: Financial Assistance
• Reduction in emergency room (ER) and urgent care visits

Oral Oncology Medication Adherence Programs

Oral oncology medications have been increasingly utilized but often involve complex regimens, intricate dosing schedules, and challenging side effect profiles, increasing the risk of patient nonadherence, therapy disruptions, and increased healthcare costs. To address these challenges, many health systems have implemented health system specialty pharmacies (HSSPs). A 2024 randomized controlled trial reviewing proportion of days covered (PDC), a measure of adherence, for patients on an oral oncology medication and engaged with an HSSP, showed pharmacist-led interventions increased adherence to oral anticancer therapies from 95% to 98% and offered comprehensive support that kept patients engaged and active on therapy.¹ PDC is a clinically relevant metric because it measures the percentage of days a patient has medication available. A high PDC is strongly associated with improved treatment efficacy, reduced disease progression, and improved overall outcomes in oncology care.

Medication Reconciliation and Patient Safety

Patients with comorbidities are more likely to receive care from multiple providers, increasing the likelihood of polypharmacy and fragmented prescribing, raising the risk of medication-related complications that may go unnoticed. Pharmacists routinely identify drug-drug interactions, inappropriate medication dosing, and duplicate therapies, as demonstrated by interventions made for patients with cancer managed through HSSPs.² When embedded into the care team, pharmacists can complete a comprehensive medication review before therapy initiation, proactively recommend therapy optimizations based on established guidelines, and collaborate with prescribers to monitor for complications.

A significant hurdle faced by patients receiving cancer treatment is the risk of toxicities and adverse events. Through proactive education prior to therapy initiation, pharmacists provide patients with clear expectations and concise recommendations to guide them through their treatment journey. However, the pharmacist’s role does not stop there. Through follow-up assessments, pharmacists monitor patients for toxicities and make additional interventions, reducing the rate of adverse reactions as well as ER and urgent care visits, improving medication adherence, and optimizing outcomes.³ One study of 26 medically integrated oncology practices reported that pharmacist-led interventions, such as dose adjustments, therapy changes, and formulary substitutions, resulted in approximately $7.06 million in cost avoidance, with an additional $11.28 million in drug waste savings.⁴

Financial Assistance

The financial burden of oral oncology medications can be significant, creating unnecessary stress for patients and their families. HSSP programs play a vital role in alleviating this burden by facilitating the financial assistance process. The HSSP team facilitates access to available manufacturer copay cards, foundation grants, and charitable assistance programs, thus reducing out-of-pocket expenses. Within some integrated HSSPs, pharmacists are involved with streamlining the prior authorization process by identifying necessary clinical information required for approval and expediting clinical appeals when necessary. These services not only enhance medication access but also free up resources to allow clinic staff, nurses, and advanced practice providers (APPs) to have more time with their patients in clinic.

Reduction in ER and Urgent Care Visits

Pharmacists play a critical role in reducing ER and urgent care visits among oncology patients by proactively managing medication-related complications and toxicities. Through comprehensive medication reviews, patient education, and timely follow-up assessments, pharmacists identify adverse effects early and intervene before they escalate to emergencies. Evidence from the URGEIM randomized clinical trial demonstrated that pharmacist-led transition-of-care programs significantly reduced ER visits for medication-related events; only 3% of patients in the intervention group returned for the same issue compared to 22.1% in usual care, a risk difference of 19.1% points.⁵ These findings underscore the value of embedding pharmacists within oncology care teams to improve safety, continuity of care, and overall patient outcomes.

Strategies for Implementation

To track the success of pharmacist integration in oncology care teams, health systems must establish standardized outcome measures that are aligned with institutional goals. Leveraging technology, such as embedding third party payer rules and preferred drug alerts within the electronic medical record, can streamline prior authorizations and minimize treatment delays. Collaboration between pharmacists, oncologists, nurses, and financial teams is essential to design protocols that enhance care coordination and cost containment. Successfully integrating pharmacists into the care team ensures they have the capacity to conduct interventions through a structured approach, leading to improved quality of care. When implementing a specialty pharmacy practice, health systems should also consider building dedicated infrastructure, integrating specialty pharmacy software with the EMR, and establishing financial navigation workflows to support copay assistance and prior authorizations. Additionally, aligning with accreditation standards such as the Utilization Review Accreditation Commission (URAC) or the Accreditation Commission for Health Care (ACHC) ensures compliance and quality in specialty pharmacy operations. Evidence from pharmacist-driven clinical interventions within a HSSP model demonstrates measurable improvements in care coordination and patient outcomes, highlighting the value of structured implementation strategies.⁶

Future Outlook

Looking ahead, as oncology care continues to evolve toward precision medicine and outcome-driven frameworks, pharmacist-led initiatives will remain indispensable to achieving excellence across quality metrics and ensuring sustainable, patient-centered care. Furthermore, the individual pharmacist will continue to play a crucial role. The continued evolution of pharmacogenomics will enable pharmacists to contribute to targeted therapeutic approaches based on individual genetic profiles. Increased telehealth integration will increase access to counseling by removing the burden of traveling to a clinic, especially for patients living in rural areas of the country. Expanded access to real-world data and predictive modeling will enable pharmacists to identify patients at risk for toxicity and nonadherence, proactively monitor, and provide outreach. The integration of AI driven clinical decision support tools will further enhance pharmacists’ ability to optimize treatment plans, predict adverse events, and align care with evolving quality measures, cementing their role as critical drivers of precision oncology.⁶

Conclusion

Pharmacists are not only medication experts, but they are also strategic partners in advancing oncology care quality. Through interventions that improve adherence, enhance safety, manage toxicities, optimize costs, and reduce ER and urgent care utilization rates, pharmacists deliver measurable benefits for both patients and health systems. HSSPs provide the structure and resources to make these interventions scalable and sustainable, ensuring excellence in patient-centered care and driving long-term value for health systems.